Skip to main navigation Skip to search Skip to main content

Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.

Translated title of the contribution: Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionCombined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.
Original languageUndefined/Unknown
Pages (from-to)1379-1385
Number of pages7
JournalAnticancer Research
Volume31
Issue number4
Publication statusPublished - 2011

Cite this